Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer

International Journal of Cancer

Volumn 135, Issue 10, 2014, Pages 2352-2361

  Kast, Karin ^a   Schmutzler, Rita K ^b   Rhiem, Kerstin ^b   Kiechle, Marion ^c   Fischer, Christine ^d   Niederacher, Dieter ^e   Arnold, Norbert ^f   Grimm, Tiemo ^g   Speiser, Dorothee ^h   Schlegelberger, Brigitte ⁱ   Varga, Dominic ^j   Horvath, Judit ^k   Beer, Marit ^l   Briest, Susanne ^m   Meindl, Alfons ^c   Engel, Christoph ^m  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY OF ULM   (Germany)

^k UNIVERSITY OF MÜNSTER   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^m UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Manchester scoring system; Validation

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER REGISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GROUPS BY AGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MANCHESTER SCORING SYSTEM; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PREDICTION; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; UNIVARIATE LOGISTIC REGRESSION ANALYSIS; BRCA1; BRCA2; BREAST TUMOR; FAMILY; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; OVARY TUMOR; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; STATISTICAL MODEL; VALIDATION;

BRCA1; BRCA2; BREAST CANCER; MANCHESTER SCORING SYSTEM; VALIDATION;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FAMILY; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; ROC CURVE;

EID: 84909969608     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28875     Document Type: Article

References (21)

1. Antoniou AC, Pharoah PP, Smith P, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-90.
2. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-15.
3. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
4. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-58.
5. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
6. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-80.
7. Evans DG, Lalloo F, Cramer A, et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-7.
8. Gerdes AM, Cruger DG, Thomassen M, et al. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet 2006;69:171-8.
9. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006;24:707-15.
10. Simard J, Dumont M, Moisan AM, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet 2007;44:107-21.
11. Thirthagiri E, Lee SY, Kang P, et al. Evaluation of BRCA1 and BRCA2 mutations and riskprediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 2008;10:R59.
12. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45:425-31.
13. Meindl A. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002;97:472-80.
14. Evans DG, Lalloo F, Wallace A, et al. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005;42:e39.
15. Fischer C, Kuchenbaecker K, Engel C, et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 2013;50:360-367.
16. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:R2.
17. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
18. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
19. Anderson WF, Jatoi I, Tse J, et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010;28:232-9.
20. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
21. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.